Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CASP6 | P55212 | 1/20 | 0.59 |
| ▸ | HTR3A | P46098 | 2/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL383207 | 0.94 | CYP1A2 (0.57) | CYP1A2POLBKDM4ELMNACASP6 | |
| SCHEMBL1459737 | 0.84 | CYP1A2 (0.61) | CYP1A2POLBKDM4ELMNACASP6 | |
| SCHEMBL29447040 | 0.77 | BACE1 (0.50) | HTR3AHRH4NR4A2ALDH1A1BACE1 | |
| SCHEMBL198060 | 0.77 | BACE1 (0.50) | HTR3AHRH4NR4A2ALDH1A1BACE1 | |
| SCHEMBL29444268 | 0.77 | CYP1A2 (1.00) | CYP1A2POLBKDM4ELMNACASP6 | |
| SCHEMBL161703 | 0.77 | CYP1A2 (1.00) | CYP1A2POLBKDM4ELMNACASP6 | |
| SCHEMBL10259445 | 0.76 | CYP1A2 (0.68) | CYP1A2POLBKDM4ELMNACASP6 | |
| Iodide SCHEMBL31142554 | 0.76 | CYP1A2 (0.95) | CYP1A2POLBKDM4ELMNACASP6 | |
| SCHEMBL21632300 | 0.76 | CYP1A2 (0.65) | CYP1A2POLBKDM4ELMNACASP6 | |
| SCHEMBL2717077 | 0.76 | CYP1A2 (0.56) | CYP1A2POLBKDM4ELMNACASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112979619-A | Method for catalyzing dehydrogenation coupling reaction of nitrogen heteroaromatic ring compound and cyclic ether by using Bronsted acid | 青岛职业技术学院 | 2021-06-18 | — | — | CN | claimed |
| CN-104447539-B | A kind of two grades, the synthetic method of three-level aromatic amides | 湖南大学 | 2017-09-15 | — | — | CN | claimed |
| CN-106565600-A | Deuterated aza aromatic compound and synthesis method thereof | 湖南大学 | 2017-04-19 | — | — | CN | claimed |
| US-4154780-A | Preparation of dithiophosphoric acid diester-halides | BAYER AKTIENGESELLSCHAFT (DE) | 1979-05-15 | — | — | US | claimed |
| US-20250082633-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC (US) | 2025-03-13 | — | — | US | disclosed |
| CN-116283759-B | Preparation method of 2-monofluoromethylquinoline and derivatives thereof | 济南大学 | 2025-02-28 | — | — | CN | disclosed |
| CN-118804912-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2024-10-18 | — | — | CN | disclosed |
| EP-4436961-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2024108774-A1 | METAL-CATALYZED DOUBLE HYDROBORATION OF NITROGEN HETEROCYCLICS | GUANGDONG TECHNION-ISRAEL INSTITUTE OF TECHNOLOGY (CN) | 2024-05-30 | — | — | WO | disclosed |
| US-20240158412-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | FAXIAN THERAPEUTICS, LLC | 2024-05-16 | — | — | US | disclosed |
| EP-4288442-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | Faxian Therapeutics, LLC (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-113862710-B | Electrochemical synthesis method of dihydro-dipyrazole [3,4-b:4',3' -e ] pyridine compound | 阜阳师范大学 | 2023-11-03 | — | — | CN | disclosed |
| EP-0038984-B1 | PROCESS FOR THE PREPARATION OF CARBONIC-ACID ESTERS | BAYER AG (DE) | 1985-07-03 | — | — | EP | disclosed |
| EP-0138176-A2 | Process for the preparation of quinolines | BASF Aktiengesellschaft (DE) | 1985-04-24 | — | — | EP | disclosed |
| EP-0132714-A2 | Process for the preparation of quinolines | BASF Aktiengesellschaft (DE) | 1985-02-13 | — | — | EP | disclosed |
| US-4416884-A | ANTIBIOTIC, BACTERICIDE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-22 | — | — | US | disclosed |
| US-4370275-A | CATALYST OF COPPER, OXYGEN, HALOGEN, AND NITROGEN BASE | BAYER AKTIENGESELLSCHAFT (DE) | 1983-01-25 | — | — | US | disclosed |
| EP-0038984-A2 | Process for the preparation of carbonic-acid esters | BAYER AG (DE) | 1981-11-04 | — | — | EP | disclosed |
| US-4154780-A | Preparation of dithiophosphoric acid diester-halides | BAYER AKTIENGESELLSCHAFT (DE) | 1979-05-15 | — | — | US | disclosed |
| US-4154780-A | Preparation of dithiophosphoric acid diester-halides | BAYER AKTIENGESELLSCHAFT (DE) | 1979-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082633-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | CYP1A2 4609/4885POLB 289/4885KDM4E 3046/4885 |
| US-20240158412-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | USP7, USP28, USP1 | CYP1A2 3471/4885POLB 2982/4885KDM4E 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.